Researched for 27 sec

Jun 23, 2025 1:28pm

Phase II PD‑(L)1 oncology assets with
no direct competitors in EU

Scanned sources in 87 languages

B2

Asset

Camrelizumab

Socazolimab

Company

Innovent

Junshi

Lead EU indic.

r/r nasopharyngeal
carcinoma

Cervical cancer

Next catalyst

ORR read‑out Q4 2025

PFS read‑out Q3 2025

Connecting securely...

Connecting securely...